APH:LSE-Alliance Pharma plc (GBX)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | LSE

Last Closing Price

GBX 107.00

Change

0.00 (0.00)%

Market Cap

GBX 0.57B

Volume

2.05M

Avg Analyst Target

N/A

Avg User Target

GBX
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Alliance Pharma plc operates as a pharmaceutical company in the United Kingdom, Republic of Ireland, Mainland Europe, the United States, and internationally. The company acquires, markets, and distributes consumer healthcare and prescription medicine products. It owns or licenses the rights to approximately 80 pharmaceutical and consumer healthcare products. The company also offers medical devices, food supplements, and cosmetics. In addition, the company provides its products under the Kelo-Cote, Nizoral, MacuShield, Vamousse, Flamma Franchise, Aloclair, Hydromol, Forceval, Optiflo, Oxyplastine, Ashton & Parsons, and Ametop brand names. Alliance Pharma plc was founded in 1996 and is headquartered in Chippenham, the United Kingdom.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-09-26 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
HIK:LSE Hikma Pharmaceuticals PLC

N/A

GBX5.52B 16.30 7.94
INDV:LSE Indivior PLC

N/A

GBX1.57B 16.00 5.94
BXP:LSE Beximco Pharmaceuticals Limite..

N/A

GBX0.92B 13.12 0.13
AMYT:LSE Amryt Pharma plc

N/A

GBX0.57B N/A 287.42
BMK:LSE Benchmark Holdings plc

N/A

GBX0.42B N/A 24.22
AGY:LSE Allergy Therapeutics plc

N/A

GBX0.24B 95.00 15.09
EAH:LSE ECO Animal Health Group plc

N/A

GBX0.22B 26.61 8.72
DNL:LSE Diurnal Group plc

N/A

GBX0.09B N/A N/A
STX:LSE Shield Therapeutics plc

N/A

GBX0.09B 53.33 125.61
MXC:LSE MGC Pharmaceuticals Limited

N/A

GBX0.07B N/A N/A

ETFs Containing APH

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 22.15% 75% C 75% C
Dividend Return 0.01% 67% D+ 15% F
Total Return 22.16% 75% C 75% C
Trailing 12 Months  
Capital Gain 44.59% 69% D+ 73% C
Dividend Return 0.74% 100% A+ 40% F
Total Return 45.33% 69% D+ 73% C
Trailing 5 Years  
Capital Gain 125.26% 92% A- 88% B+
Dividend Return 10.71% 80% B- 45% F
Total Return 135.97% 92% A- 87% B+
Average Annual (5 Year Horizon)  
Capital Gain 19.45% 62% D- 77% C+
Dividend Return 1.74% 80% B- 55% F
Total Return 21.19% 54% F 76% C
Risk Return Profile  
Volatility (Standard Deviation) 28.49% 92% A- 44% F
Risk Adjusted Return 74.37% 100% A+ 82% B-
Market Capitalization 0.57B 79% C+ 59% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 32.42 50% F 25% F
Price/Book Ratio 2.00 71% C- 44% F
Price / Cash Flow Ratio 13.80 36% F 33% F
EV/EBITDA 18.75 40% F 35% F
Management Effectiveness  
Return on Equity 6.52% 71% C- 47% F
Return on Invested Capital 6.07% 79% C+ 71% C-
Return on Assets 4.66% 71% C- 63% D
Debt to Equity Ratio 49.23% 43% F 32% F
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.58 69% D+ 81% B-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (GBX)

Quarterly Financials (GBX)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector